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Abstract 
Background/Aims: 
To evaluate the feasibility and the effects of a group cessation program for co-smokers of 
cannabis and tobacco. 
Methods: 
Using a within-participants design with pre-, post-, and 6-month follow-up assessments, 
feasibility and changes in substance use and mental health were evaluated. A total of 77 co-
smoking adults participated in the study. 
Results: 
Within nine months the target sample size was reached. Treatment retention was 62.3%, and 
only three participants discontinued the treatment due to severe problems (problems with 
concentration, sleeping problems, depressive symptoms, and/or distorted perceptions). 
41.5% and 23.4% reported abstinence from cigarettes, cannabis, or both at the end-of-
treatment and the follow-up, respectively. The separate abstinence rates for cigarettes and 
cannabis were 32.5% and 23.4% (end-of-treatment) and 10.4% and 19.5% (follow-up). 13.0% 
(end-of-treatment) and 5.2% (follow-up) achieved cotinine-validated dual-abstinence. Over 
the study period, significant decreases of tobacco-use and cannabis-use and significant 
improvements in further outcomes (problem drinking, cannabis use disorder symptoms, 
nicotine dependence, depression, anxiety) were achieved.  
Conclusion: 
The evaluated intervention for co-smokers is feasible regarding recruitment, intervention 
retention, and intervention safety. The promising results regarding substance use behaviour 
and mental health suggest an evaluation of effectiveness in a randomized controlled trial. 
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Introduction  
Cannabis use is associated with a range of problems including those related to mental and 
physical health, cognition, and educational outcomes [1,2]. Tobacco smoking is among the 
three leading risk factors for the global disease burden [3]. Both substances are often used 
concurrently. Tobacco smokers are more likely to use cannabis compared with non-smokers 
[4] and vice versa [5]. The mechanisms linking these two substances most likely extend 
beyond a shared vulnerability and the co-use of substances in general [6]. Among these 
connecting mechanisms are the shared route of administration (i.e. both substances are 
typically smoked) and co-administration (e.g. tobacco is added to cannabis joints in a process 
known as “mulling”) [7]. In Australia, mulling is a widespread way of delivering cannabis [8–
10] and in Switzerland 90% of cannabis users smoke joints mixed with tobacco [11].  
This strong relationship between tobacco and cannabis use is also relevant in the context 
of cessation. Epidemiological evidence shows that co-smokers make fewer attempts at 
quitting tobacco use compared with tobacco-only smokers [12] and are less successful at 
quitting [13]. Compared with tobacco-only smokers, co-smokers have poorer outcomes when 
participating in tobacco-cessation interventions [14]. Correspondingly, cannabis-dependence 
treatments are less effective among individuals who also smoke tobacco [15,16]. Moreover, a 
laboratory study of non-treatment-seeking marijuana users revealed that co-smokers of 
cigarettes were more likely to relapse after a phase of cannabis abstinence compared with 
non-cigarette smokers [17]. Smoking cigarettes is assumed to provide behavioural and 
physiological cues for cannabis smoking and vice versa, which may explain the increased 
probability of relapsing among co-smokers [7,15]. In line with this hypothesis, a study 
analysed adolescents in substance-abuse treatment and found that never-smokers and those 
non-smokers who quit using tobacco during their marijuana treatment had a lower risk of 
marijuana relapse than those who continued or initiated tobacco smoking during treatment 
[16]. 
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Despite the strong relationship between these substances, interventions typically target 
only one substance while addressing the other marginally or not at all. The historical 
development of the treatment and prevention systems in many industrialised countries might 
explain the lack of combined interventions. While cannabis dependence is usually treated in 
the psychiatric care system, interventions for tobacco users are part of the general public 
health system [18,19]. Recently, several reviews and a demand analysis identified a need for 
interventions tailored to co-smokers of tobacco and cannabis [7,20–22]. To date, one small 
pilot study evaluated individual cognitive behavioural therapy combined with nicotine 
replacement therapy (NRT) for co-occurring cannabis and nicotine dependence [23]. The 
seven participants who completed the intervention reduced their tobacco use while 
maintaining their cannabis use level. Similarly, tobacco smoking cessation interventions 
integrated in treatments of alcohol or opioid dependence have achieved positive results [24–
26], which indicates that tobacco cessation interventions do not undermine other substance 
abuse treatments. Instead, dual treatment programs generate putatively better outcomes with 
regard to one or both targeted behaviours [18,27,28]. 
The current study aimed to test the feasibility and effects of a group cessation 
intervention for co-smokers targeting cannabis and tobacco use simultaneously. This study is 
the first to evaluate these aspects with regard to the dual-cessation of cannabis and tobacco 
use in a group setting. Furthermore, it is a novelty to examine dual-abstinence from cannabis 
and tobacco. 
 
Methods 
Study design and procedure 
This study used a within-participant design with pre-, post-, and 6-month follow-up 
assessments to evaluate the feasibility of an integrative group cessation intervention that 
targeted co-smokers of cannabis and tobacco. Two addiction treatment centres in Zurich and 
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Winterthur, Switzerland, offered the courses between January and October 2012. The Ethics 
Committee of the Canton of Zurich reviewed and approved this study (KEK-StV-Nr.23/11), 
which was designed in accordance with the Helsinki declaration. All participants provided 
written informed consent. The study is registered at Current Controlled Trials 
(ISRCTN15248397). 
Baseline data were collected via questionnaires administered during an information 
evening or via the post for participants who did not attend the information evening. 
The end-of-treatment (EOT) assessment was conducted during the last session of the 
course. Participants completed a questionnaire and provided a saliva sample. To maximise 
response rates, we attempted to collect data from individuals who had discontinued treatment. 
Therefore, these individuals received the questionnaire and the salivette for the saliva sample 
via the post. Participants who did not return the questionnaire were contacted via telephone or 
e-mail and motivated to complete the questionnaire. If contact was not established or the 
participants reported that they did not receive or lost the questionnaire, then we resent the 
questionnaire. When the reminders were unsuccessful, participants received a brief version of 
the questionnaire that only assessed the primary outcomes.  
The follow-up measurement was conducted six months after the designated quit date. 
All participants received a questionnaire and a salivette via the post. The measurement 
procedure was comparable with the EOT assessment, the only difference being that we resent 
the questionnaire up to three times before using brief online or phone questionnaires. 
Participants who did not complete the intervention were additionally contacted by phone or e-
mail to assess their reasons for discontinuation. Moreover, 500 Swiss Francs were raffled to 
one of the participants who returned their completed questionnaire and saliva sample. 
For recruitment, a press release announcing the intervention and the accompanying 
study was issued via local newspapers, television, and the radio to recruit participants. In 
addition, counselling centres for addiction prevention and treatment, psychiatrists, and health 
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care centres received leaflets and brochures and were ask to distribute them. Two social media 
platforms and an advertisement in the online edition of a popular free newspaper were used to 
recruit online. All recruitment methods referred potential participants to the intervention’s 
website for more information. Finally, an information evening was offered. The publication 
regarding the development of the intervention provides a detailed description of the 
recruitment process [22].  
 
Participants  
The inclusion criteria for study participation were (1) an age of 18 years and older; (2) 
cannabis smoking at least once per week; and (3) daily tobacco cigarette, pipe, or cigar 
smoking. The exclusion criteria included (1) a current, serious psychiatric illness or a history 
of psychosis, schizophrenia, or bipolar type I disorder; (2) other smoking cessation treatment 
at study entry; and (3) an inability to read or write in German.  
Figure 1 provides an overview of the participant flow through the study. A total of 104 
people were screened for eligibility. Of these, 12 declined to participate, six provided 
informed consent but never appeared at a course session, and three were excluded from 
participation because they no longer smoked both substances. Of the 83 participants who 
began the intervention, four participants were admitted to attend the courses but not included 
in the study because they smoked cannabis less than once per week (n = 2) or were in 
treatment for psychosis (n = 2). Two participants were retrospectively excluded from the 
study: One participant admitted during the study that she had already quit using cannabis prior 
to the baseline assessment; the other participant did not return the informed consent form. 
Thus, 77 (74.0%) of the screened participants were included in the study. 
 
Intervention 
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The intervention was structured into five to six weekly 2-hour group therapy sessions and 
guided by two course instructors. Additionally, the course instructors offered each participant 
one individual counselling session on request and recommended NRT and varenicline. At 
least one of the course instructors had to be a psychiatrist to guarantee the offer of 
prescription pharmacotherapy to reduce acute withdrawal symptoms or eventual 
exacerbations of severe psychiatric symptoms. During the first implementation phase, three 5-
session courses were conducted with 13, 16, and 11 participants. Based on the course 
instructors’ feedback provided after the first implementation phase, the course content was 
redistributed over six sessions. In the second implementation phase, four 6-session courses 
were conducted with 6, 8, 13, and 10 participants. All participants were expected to refrain 
from tobacco and cannabis use after the third session (the “quit day”). 
The instructors received a therapist manual containing instructions for guiding the 
sessions. To the participants they distributed a smoking diary and a workbook, containing 
background information, an overview of the course structure and content, and work sheets to 
reflect on personal reasons for cessation and develop and write down personal strategies. The 
treatment included therapeutic elements derived from motivational interviewing [29], 
cognitive behavioural therapy, the relapse prevention model [30], and self-control practices. 
Although most of these principles and techniques were applied throughout the duration of the 
course, the emphasis on the application of each principle differed. Motivational enhancement 
strategies predominated in the early sessions of the intervention to address participants’ 
ambivalence about quitting and strengthen their motivation to change. In the following 
sessions, self-control practices were highlighted, such as the analysis of one’s own smoking 
behaviour with the help of a smoking diary. After the Quit Day, the focus was set on relapse 
prevention by promoting the development of personal strategies to avoid or cope with tobacco 
and cannabis use triggers. During the first 30 to 60 minutes of each session, participants and 
course instructors discussed the smoking behaviour of the preceding week and could share 
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experiences and problems. Here, participants received support both from the other participants 
and from the instructors. Afterwards, they worked on the chapters of the manual scheduled for 
the session.  
Participants who continued using tobacco, cannabis, or both after the Quit Day were 
encouraged to make an additional attempt to quit. To avoid the attrition due to participant 
failure, the course instructors could promote reducing use or changing to a less harmful form 
of administration (e.g. orally or with a vaporiser) [31] when participants failed to quit several 
times.  
A detailed description of the intervention and its development has been published 
elsewhere [22]. 
 
Measures 
Intervention feasibility. To determine the feasibility of the intervention, we used recruitment 
success, intervention retention, study attrition, intervention safety, and intervention 
acceptability as indicators. 
We aimed to recruit around 80 participants. Although feasibility studies are often 
conducted with smaller sample sizes, we chose this considerably high number in order to have 
a sufficient sample size for subgroup analyses.  
Intervention retention was defined as not missing more than one session, or missing two 
sessions but not the last session. The reasons for intervention dropout were assessed among 
the dropouts using a multiple-choice question in which more than one answer was acceptable 
(specified in Table 2); dropouts were also provided the opportunity to explicate additional 
non-listed reasons.  
To evaluate intervention safety, we explicitly enquired the experience of severe 
problems due to course participation as reason for course dropout. Using semi-structured 
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interviews conducted with the course instructors after course implementation, we also 
assessed potential hospitalisation among intervention completers as further measure of safety. 
Participant satisfaction, i.e. acceptability, was measured with the item, “Would you 
recommend the course to a friend in a similar situation?” with a scale ranging from 0 
(“definitely no”) to 5 (“definitely yes”) at the EOT assessment. In addition, at the follow-up 
participants were asked whether they had recommended the course to anyone.  
 
Cannabis and tobacco use. Baseline cannabis use for the previous seven days was measured 
according to the timeline follow-back (TLFB) method which has been shown to be a self-
report measure with high agreement rates with biological measures [32]. Baseline cigarette 
use frequency was measured in terms of the daily amount of cigarettes smoked during a 
typical smoking day, corrected for the number of smoking days during the past month. At the 
EOT and 6-month follow-up, 7-day cigarette and cannabis use frequency were assessed using 
the TLFB method. Participants who reported that they did not use one substance were 
considered abstinent with regard to this substance. Dual-abstinence was defined as reporting 
neither cigarette nor cannabis use. Salivary cotinine was used to analytically verify self-
reported dual-abstinence, with a cut-off value of 5-ng/ml cotinine. Participants who reported 
dual-abstinence but had a positive cotinine test were counted as non-abstinent. If this 
inconsistency could be explained via sustained NRT, then participants were counted as 
abstinent. Because the use of NRT was only assessed at EOT, this correction could not be 
applied for the follow-up assessment. Cannabis abstinence was not analytically validated 
because of the lack of methods of salivary delta-9-tetrahydrocannabinol (THC) verification 
that are valid and applicable under the sampling and transport conditions [33]. Furthermore, 
the course instructors were strongly opposed to collecting urine THC samples. 
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Problematic cannabis use was measured using the Cannabis Use Disorders 
Identification Test (CUDIT; [34]) which has been validated in a Swiss sample [35]. Nicotine 
dependence was measured using the Fagerstrom Test for Nicotine Dependence (FTND; [36]).  
 
Alcohol use und mental health. Problematic alcohol use was measured using the Alcohol 
Use Disorders Identification Test - Consumption (AUDIT-C; [37]). To assess mental health 
the German short version of the Beck Depression Inventory (BDI-V; [38,39]) and the Beck 
Anxiety Inventory (BAI; [40,41]) were used. Continuous scales were used instead of cut-off 
values to better capture the variability across the range of symptoms for all variables. The 
CUDIT was administered at baseline and the 6-month follow-up; all other variables were 
additionally assessed at the EOT. 
 
Baseline variables. The demographic variables gender, age, highest educational attainment, 
and employment status were assessed at baseline. Furthermore, regular medication and 
lifetime use of cocaine and ecstasy were measured. Participants were also asked to indicate 
whether they have been diagnosed with one or several of the following psychiatric diseases: 
Schizophrenia, depression, anxiety disorder, attention deficit hyperactivity disorder, and/or 
other psychiatric diseases. Readiness to quit tobacco and cannabis, respectively, was assessed 
using readiness rulers [42] with a scale ranging from 1 (“not at all”) to 10 (“very much”).  
 
Data analyses 
We analysed the differences between study dropouts and completers with regard to the 
baseline variables. Given the small number of dropouts, we used Mann-Whitney U tests and 
Fisher’s exact tests.  
To examine abstinence, descriptive tables were created to provide an overview of the 
number of participants abstinent from (1) cannabis, (2) cigarettes, or (3) both according to the 
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self-report and the biochemical validation at the EOT and follow-up assessments. We reported 
abstinence rates based on complete case analyses (CCAs) and on an analysis in which all 
missing participants were regarded as non-abstinent (MAU). 
To analyse whether cannabis use frequency, cigarette use frequency, problematic 
cannabis use, nicotine dependence, problematic alcohol use, and mental health changed over 
time, we used generalised estimating equations (GEEs). This method accounts for the 
correlated nature of within-participant repeated-measures data. One of the advantages of this 
method is that it is consistent with intent-to-treat analyses because it accounts for all 
participants, regardless of missing values on EOT or follow-up assessments [43]. An 
exchangeable working correlation matrix was applied to each model, and measurement time 
(i.e. baseline, EOT, and follow-up) was entered as a predictor. To model variables with 
distributions characterised by a high proportion of zeroes (i.e. nicotine dependence and the 
frequency of cigarette and cannabis use) negative binomial models with a log link function 
were applied. A normal model with an identity link function was chosen for the other 
outcomes.  
We also conducted exploratory subgroup analyses to examine whether participants who 
failed to achieve dual-abstinence but successfully quit one substance compensated for their 
abstinence via the increased use of the remaining substance. Therefore, we calculated change 
scores for each substance by subtracting the use frequencies reported at the EOT and follow-
up, respectively, from those reported at baseline. Then, we compared these change scores 
between abstainers of only one substance and participants who continued to co-smoke using 
Mann-Whitney U tests. 
All analyses were conducted using IBM SPSS version 20.0 [44]. 
 
Results 
Participant characteristics and study attrition analysis 
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At the EOT and follow-up assessments, 60 (77.9%) and 62 (80.5%) participants, respectively, 
provided at least their self-report data concerning the frequency of cannabis and cigarette use 
over the last week (Figure 1). Of those who indicated dual-abstinence, 10 (90.9%) and 4 
(60.7%) participants provided cotinine samples at the EOT and follow-up, respectively.  
Table 1 shows socio-demographic characteristics and substance use behaviour of the 
sample at baseline and the comparison between participants who provided self-report data 
regarding their use frequency at the 6-month follow-up (n = 59) and those who did not (n = 
18). Significance tests did not yield between-group differences.  
 
---Table 1--- 
 
Regarding prior quit attempts, 58 (75.3%) and 61 (79.2%) participants had already 
made at least one attempt to quit cannabis or/and tobacco, respectively. Only 18 (23.4%) 
participants had already tried to quit both substances simultaneously. With regard to 
psychiatric diseases, 11 (14.3%), 2 (2.6%), and 2 (2.6%) participants reported that they have 
been diagnosed with depression, anxiety disorder, or/and ADHD, respectively.  
 
Treatment attendance, the reasons for treatment dropout, and acceptability 
Of the 77 study participants, 48 (62.3%) completed the intervention. While 25 participants 
(32.5%) attended all sessions, 11 participants (15.6%) attended fewer than 50% of the 
sessions, and one participant (1.3%) attended only one session. Only seven participants used 
individual counselling; the majority of these participants spoke only briefly with the course 
facilitators before or after the course session or during the short break, but they did not 
arrange a separate counselling session. 
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Twenty-one (72.4%) of the 29 participants who discontinued the intervention provided 
reasons for course disruption (Table 2). There were no reports of any hospitalisations as a 
consequence of course participation.  
At the EOT assessment, 57 participants responded to the question regarding whether 
they would recommend the intervention to someone else. The majority of these participants 
(33, 57.9%) chose the highest value of 5 (i.e. “definitely yes”, M = 4.2, SD = 1.1). By the 
follow-up, 24 of 44 (54.5%) participants had already recommended the course to another 
person.  
 
---Table 2--- 
 
Cannabis and tobacco use 
A total of 32 participants (41.5%) reported either single or dual-abstinence at the EOT 
assessment. At the follow-up, 18 participants (23.4%) reported abstinence from one or both 
substances. Table 3 provides an overview of the number of abstinent participants based on the 
self-report and biochemical validation data, the response rates, and the corresponding 
abstinence rates for each time point. Of the 11 participants who indicated dual-abstinence at 
the EOT assessment, one did not provide a cotinine sample and was therefore regarded as 
non-abstinent. Another two participants returned positive cotinine samples but were counted 
as abstinent because they were using nicotine patches. At the follow-up, two of the six 
participants who reported dual-abstinence did not return their cotinine sample and were 
counted as non-abstinent. 
 
---Table 3--- 
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Tables 4 displays descriptive results of the frequency of cannabis and tobacco use, of 
problematic cannabis use and of nicotine dependence. All outcomes improved over study 
time. The GEE analyses revealed that these changes were significant (Table 5). 
 
---Table 4--- 
---Table 5--- 
 
The results of the exploratory analyses of compensatory use after quitting only one 
substance are displayed in Table 6. According to the descriptive results, the use frequency did 
not increase among participants who continued smoking two substances or those who quit one 
substance; rather, participants decreased their use. We did not detect group differences with 
regard to the amount of reduction. However, the respective sample sizes were low and, in the 
case of cannabis use frequency at the follow-up assessment, a significance test was omitted. 
 
---Table 6--- 
 
Alcohol use and mental health 
Table 4 shows the descriptive results of problematic alcohol use and of depression and 
anxiety symptoms, all of which improved from baseline at the EOT and follow-up 
assessments. The GEE modelling results revealed significant time effects for all three 
outcomes (Table 5).  
 
Discussion  
The results of this study support the feasibility of the evaluated integrative group cessation 
program. First, recruitment was successful: within a recruitment period of nine months 77 co-
smokers could be included in the feasibility study. Thus, the target sample size of around 80 
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participants was reached and recruitment could be stopped two months earlier than planned. 
Furthermore, 62.3% of participants completed the intervention. This retention rate is similar 
to the rate achieved in the pilot study that examined individual treatment of tobacco and 
cannabis co-smokers (58.3%) [23]. In addition, participants’ high levels of satisfaction (based 
on their recommendation levels) illustrated acceptability. A more detailed evaluation of 
intervention acceptability is presented in an earlier publication [22]. We did not find evidence 
of hospitalisation due to course participation and only three participants indicated that severe 
problems due to their simultaneous cessation (attempts) were among their reasons for 
discontinuing the intervention. This suggests that the intervention is considerably safe. 
However, the finding that severe problems were experienced must be addressed when 
implementing the program in the future (e.g. in promoting the use of individual counselling, 
preparing participants for the possibility of severe problems, and motivating them to contact 
the course facilitators in the event they experience such problems). 
Ten (13.0%) and four (5.2%) participants achieved cotinine-verified dual-abstinence 
from tobacco and cannabis at the EOT and the follow-up, respectively. The self-reported 
single-abstinence rates at the EOT and follow-up assessments were higher, i.e. for cannabis 
23.4% and 19.5%, respectively, and for cigarettes 32.5% and 10.4%, respectively. The only 
other study of a combined intervention did not report abstinence rates [23]. 
Furthermore, participants reduced their use of cannabis and cigarettes and also 
improved regarding their problematic alcohol use and mental health during the study period, 
indicating the potential effectiveness of the intervention. The subgroup analyses regarding the 
differential changes in the use frequency between the quitters of one substance and those who 
continued co-smoking indicated that quitting one substance does not lead to a compensatory 
increase in the remaining substance when both substances are targeted in an integrative 
treatment, such as the present one. A substitution effect has been a major concern with regard 
to implementing tobacco smoking interventions within other substance abuse treatments [18]. 
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One limitation of this study is that the study attrition limits the generalisability of the 
results. However, the dropout analysis revealed that participants who provided follow-up data 
did not differ significantly from dropouts with regard to their baseline characteristics. Further 
limitations concern the measurement of the outcomes related to cannabis and tobacco use. 
According to the aim of the present intervention, i.e. dual-cessation of cannabis and tobacco 
use, we aimed at quantifying simultaneous behaviour change. For this, we had to rely on a 
combination of validated measurement instruments for single substance use behaviour 
because there is no validated psychometric measurement instrument for simultaneous change 
so far. We therefore used dual-abstinence of both substances according to TLFB-assisted self-
reports as outcome measure. To progress the evaluation interventions targeting at dual 
behaviour change, appropriate instruments should be constructed and validated. Another 
limitation is the lack of an analytical validation for cannabis abstinence. Although salivary 
cotinine samples are an appropriate measure to validate tobacco abstinence, a reliable method 
for detection of THC and/or its metabolite THC-carbonic acid and the interpretation of 
corresponding analytical findings, respectively, is still lacking [33]. Nevertheless, the TLFB 
assisted self-report is a valid measure of cannabis use frequency [32,45,46]. An additional 
limitation of this study is that the presence of NRT, which might explain the inconsistencies 
between self-reported and cotinine-validated abstinence rates, was not assessed at the 6-month 
follow-up assessment.  
Randomised trials must be conducted to evaluate the efficacy of integrative 
interventions compared with single interventions among co-smokers. Moreover, future studies 
should implement feasible blood or urine verification methods for cannabis abstinence and 
evaluate alternatives to a designated quit date for all participants and both substances. For 
instance, staggered quit dates for tobacco and cannabis might be useful because evidence 
suggests that recent cigarette abstinence does not decrease the likelihood of a cannabis relapse 
[17]. Furthermore, a clinical comparison study found that withdrawal was more severe during 
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simultaneous cessation than during single cessation; however, this difference was only for a 
short duration, and substantial inter-individual variability was reported [47]. Finally, 
analysing how treatment goals other than dual-abstinence affect the treatment outcomes might 
be helpful in improving treatment success. For example, a tobacco-abstinence goal combined 
with a cannabis-use-moderation goal might be an alternative because a study that evaluated a 
guided self-change treatment found that most cannabis users chose to reduce their cannabis 
use rather than to abstain [48]. However, a cannabis abstinence goal combined with a reduced 
tobacco use goal is also a possibility because tobacco cessation might be a barrier to seeking 
treatment [49]: Cannabis users seem to be less likely to select an abstinence goal for tobacco 
use compared with tobacco-only smokers [50]. 
In summary, the present study demonstrated the feasibility of an integrative group 
cessation program that targeted co-smokers of cannabis and tobacco. Furthermore, promising 
changes in tobacco, cannabis, and alcohol use behaviour and in mental health were observed. 
Clinicians treating participants with cannabis use disorders should not hesitate to also 
integrate treatment of cigarette use and vice versa. In order to evaluate the effectiveness of the 
dual-intervention, we aim at conducting a randomized controlled trial in the near future. 
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TABLES 
Table 1. Baseline participant characteristics and the differences between study completers 
(followed up after 6 months; n = 59) and dropouts (n = 18). 
Characteristics Total Completers Dropouts p 
Demographic characteristics     
Age in years, mean (SD) 32.4 (8.2) 32.5 (7.8) 32.0 (9.7) .796
Women, n (%)  19 (24.7) 16 (27.1) 3 (16.7) .535
Education, n (%) a  .591
Incomplete secondary  9 (11.8) 8 (13.8) 1 (5.6) 
Secondary 43 (56.6) 31 (53.4) 12 (66.7) 
Higher 24 (31.6) 19 (32.8) 5 (27.8) 
Employed, n (%) b 62 (82.7) 48 (84.2) 14 (77.8) .499
Cannabis use  
Use frequency per day, mean (SD) 3.0 (1.9) 2.9 (1.8) 3.5 (1.9) .219
Age of onset of cannabis use, mean 
years (SD) 
16.6 (3.3) 16.8 (3.6) 15.8 (2.0) .436
CUDIT score, mean (SD) 18.6 (7.1) 18.7 (7.6) 18.2 (5.1) .597
Tobacco smoking   
Cigarettes/pipes per day, mean (SD) 16.1 (9.0) 16.5 (9.6) 14.7 (6.8) .404
Age of onset of tobacco use, mean 
years (SD) 
15.7 (2.4) 15.7 (2.6) 15.7 (1.4) .458
FTND score, mean (SD) 4.0 (2.0) 4.0 (2.1) 4.0 (1.7) .950
Other substance use  
AUDIT-C score, mean (SD) 5.6 (2.3) 5.7 (2.1) 5.1 (2.9) .145
Lifetime use of cocaine, n (%)  48 (62.3) 37 (62.7) 11 (61.1) 1.000
Lifetime use of ecstasy, n (%)  45 (58.4) 35 (59.3) 10 (55.6) .797
Readiness to quit c  
Cannabis, mean (SD) 7.5 (2.2) 7.5 (2.2) 7.7 (2.3) .521
Tobacco, mean (SD) 8.3 (1.8) 8.3 (1.8) 8.3 (1.8) .865
Physical/mental health   
BDI-V score, mean (SD) 35.7 (19.1) 35.7 (19.3) 35.6 (18.8) .914
BAI score, mean (SD) 12.7 (9.5) 12.5 (9.4) 13.2 (9.8) .824
Regular use of medication, n (%) 9 (12.0) 8 (14.0) 1 (5.6) .678
Mann-Whitney U-tests and Fisher’s exact tests; a missing values: n = 1; b missing values: n = 
2; c Readiness to quit was measured using contemplation ladders ranging from 1 (not at all) to 
10 (very much); AUDIT-C = Alcohol Use Disorder Identification Test - Consumption, scale 
ranges from 0 to 12; BAI = Beck Anxiety Inventory, scale ranges from 0 to 63; BDI-V = 
simplified Beck Depression Inventory, scale ranges from 0 to 100; CUDIT = Cannabis Use 
Disorder Identification Test, scale ranges from 0 to 40; FTND = Fagerstrom Test for Nicotine 
Dependence, scale ranges from 0 to 10; SD = standard deviation 
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Table 2. Reasons for intervention disruption, assessed among non-completers (multiple 
answers possible, n = 21). 
Reasons for intervention disruption N % of 
respondents
I had severe problems due to the cessation (attempt). 3 14.3
Problems with concentration 1 4.8
Sleeping problems 3 14.3
Depressive symptoms 2 9.5
Distorted perceptions 1 4.8
Problems with breathing 0 0.0
Other 1 4.8
I had no longer had time for the course sessions. 8 38.1
I had already quit using cannabis before the Quit Day. 3 14.3
I had already quit using tobacco before the Quit Day. 3 14.3
I did not want to quit using cannabis (any more). 2 9.5
I did not want to quit using tobacco (any more). 4 19.1
I did not want to simultaneously quit using tobacco and cannabis 
(any more). 
5 23.8
I felt that the intervention did not help me. 7 33.3
Other reasons 10 47.6
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Table 3. Seven-day abstinence rates at the end-of-treatment and 6-month follow-up 
assessments, N = 77. 
Outcome n 
abstinent 
n missing 
values 
% of CCA 
sample 
% of MAU 
sample 
End-of-treatment assessment     
Cannabisa abstinence (self-report) 18 16 29.5 23.4 
Cigarette abstinence (self-report) 25 17 41.7 32.5 
Dual-abstinence (self-report) 11 17 18.3 14.3 
Dual-abstinence (cotinine-verified) 10 18 16.9 13.0 
6-month follow-up assessment     
Cannabisa abstinence (self-report) 15 16 24.6 19.5 
Cigarette abstinence (self-report) 8 18 13.6 10.4 
Dual-abstinence (self-report) 6 17 10.0 7.8 
Dual-abstinence (cotinine-verified) 4 19 6.9 5.2 
a including co-administered tobacco; CCA sample = complete cases only; MAU sample = 
missings treated as users 
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Table 4. Means and standard deviations of repeatedly measured outcomes at baseline, the 
EOT assessment, and the 6-month follow-up assessment among complete cases. 
Outcome n  
complete cases 
Baseline 
Mean (SD) 
EOT  
Mean (SD) 
Follow-up  
Mean (SD) 
Cannabis use frequency 54 2.99 (1.96) 1.14 (1.97) 1.60 (1.76) 
Cigarette use frequency 54 16.23 (9.96) 5.49 (11.62) 10.76 (13.01) 
CUDIT  39 18.41 (8.17) -- 11.33 (7.63) 
FTND  38 3.76 (2.26) 1.13 (1.99) 1.92 (2.36) 
AUDIT-C  40 5.20 (1.88) 4.82 (1.85) 4.70 (2.17) 
BDI-V  40 34.43 (21.19) 25.00 (19.26) 23.72 (18.58) 
BAI  40 11.92 (10.25) 7.85 (9.35) 5.84 (5.74) 
Lower values represent better outcomes for all scales. AUDIT-C = Alcohol Use Disorder 
Identification Test, Consumption, scale ranges from 0 to 12; BAI = Beck Anxiety Inventory, 
scale ranges from 0 to 63; BDI-V = simplified Beck Depression Inventory, scale ranges from 
0 to 100; CUDIT = Cannabis Use Disorder Identification Test, scale ranges from 0 to 40; 
EOT = end-of-treatment assessment; FTND = Fagerstrom Test for Nicotine Dependence, 
scale ranges from 0 to 10; EOT = end of treatment; SD = standard deviation 
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Table 5. Generalised estimating equation (GEE) models of the repeatedly measured outcomes 
over time. 
Dependent variables Coefficient (IRR/b) SE 95% CI p 
Cannabis use frequency a 0.699 0.073 (0.605; 0.807) < .001 
Cigarette use frequency a 0.819 0.059 (0.730; 0.919) .001 
CUDIT b -3.590 0.548 (-4.663; -2.517) < .001 
FTND a 0.687 0.082 (0.585; 0.807) < .001 
AUDIT-C b -0.347 0.117 (-0.577; -0.117) .003 
BDI-V b -5.948 1.335 (-8.565; -3.332) < .001 
BAI b -3.143 0.532 (-4.186; -2.101) < .001 
The predictor in every model is time; Time 1 = baseline, Time 2 = end-of-treatment 
assessment, Time 3 = 6-month follow-up assessment; CUDIT was measured only at Time 1 
and Time 3; a models are based on a negative binomial model with a log link function; b 
models are based on a normal model with an identity link function; lower values represent 
better outcomes for all scales. AUDIT-C = Alcohol Use Disorder Identification Test - 
Consumption; BAI = Beck Anxiety Inventory; BDI-V = simplified Beck Depression 
Inventory; CI = confidence interval; CUDIT = Cannabis Use Disorder Identification Test; 
FTND = Fagerstrom Test for Nicotine Dependence; IRR = incident rate ratio, displayed for 
negative binomial models; SE = standard error 
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Table 6. Mann-Whitney U tests, applied to compare the use frequency change scores between 
participants who quit one substance and those who continued using both. 
Comparisons n Baseline 
M  
(SD) 
EOT 
M  
(SD) 
Follow
-up 
M  
(SD) 
Difference 
M  
(SD) 
P-value
Cannabis use frequency of 
tobacco-only abstainers at EOT 
14 3.2 
(1.8) 
1.0 
(1.3) 
-- -2.2  
(1.7) 
Cannabis use frequency of co-
smokers at EOT 
35 2.9  
(1.8) 
1.6 
(2.3) 
-- -1.2  
(2.5) 
.188
Cannabis use frequency of 
tobacco-only abstainers at FU 
2 5.5 
(1.5) 
-- 4.1 
(1.2) 
-1.4 
(0.3) 
Cannabis use frequency of co-
smokers at FU 
51 2.9 
(1.8) 
-- 1.7 
(1.7) 
-1.2 
(1.9) 
--
Cigarette use frequency of 
cannabis-only abstainers at 
EOT 
6 23.7  
(19.1) 
20.3 
(28.2) 
-- -3.5 
(12.6) 
Cigarette use frequency of co-
smokers at EOT 
42 15.5  
(8.0) 
5.2 
(6.9) 
-- -10.2 
(7.5) 
.142
Cigarette use frequency of 
cannabis-only abstainers at FU 
7 26.1  
(15.6) 
-- 25.8 
(24.1) 
-0.4 
(10.7) 
Cigarette use frequency of co-
smokers at FU 
46 15.4 
(7.9) 
-- 10.3 
(8.9) 
-5.2 
(6.9) 
.259
EOT = end-of-treatment assessment; M = Mean; SD = standard deviation 
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FIGURE LEGEND 
 
 
Figure 1. Participant flow 
